Rogaratinib Completed Phase 1 Trials for Neoplasm Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03788603Rogaratinib (BAY1163877) in Chinese Patients
NCT01976741Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)